Jefferies Healthcare Conference Day 3: Sequenom, Agilent

Sequenom reiterated its plans to launch its T21 test by the end of the year as an LDT, while Agilent is looking to move into the top ranks as a life science instrument vendor.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.